Navigation Links
New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
Date:9/16/2009

of Santaris Pharma A/S.

Dr. Levin has 15 years of experience in RNA-based research and more than 25 years of experience in the pharmaceutical industry. Prior to joining Santaris Pharma A/S, Dr. Levin was Senior Vice President of Drug Development at Isis Pharmaceuticals where he was instrumental in advancing more than a dozen RNA-based antisense drugs from basic research to clinical development.

"We are pleased that Dr. Levin has joined our management team to establish operations in the US and oversee global development programs for Santaris Pharma A/S," said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. "His wealth of RNA-based research and development experience and industry knowledge will be instrumental in leveraging the Company's proprietary Locked Nucleic Acid chemistry and Drug Discovery Engine to explore new licensing opportunities and scientific collaborations, increase visibility with capital markets and attract leading scientists."

Santaris Pharma A/S recently achieved a breakthrough in medical science as the first company to advance a microRNA-targeted therapy into human clinical trials. A single-dose Phase 1 trial in healthy volunteers has now been completed and an additional Phase 1 multiple ascending-dose study is planned.

The drug SPC3649 specifically targets microRNA-122 (miR-122), a host factor for Hepatitis C virus replication. In 2008, Santaris Pharma A/S published the results of successful microRNA silencing with SPC3649 in non-human primates in Nature(1).

"Advancing the first microRNA therapy into human clinical trials is a testament to Santaris Pharma A/S leadership in the field," said Henrik Orum, Vice President and Chief Scientific Officer at Santaris Pharma A/S. "Our proprietary LNA Drug Platform incorporating short single-stranded LNAs offers higher affinity, greater specificity and remarkable potency compared to other
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
2. Californias International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
5. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
6. Research breakthrough will lead to more accurate weather forecasts
7. OMT announces a breakthrough in the development of a novel human antibody platform
8. New drugs faster from natural compounds: A UC San Diego breakthrough
9. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
10. Light sensor breakthrough could enhance digital cameras
11. DNA2.0 Awarded US Patents for Breakthrough Gene Optimization Technology -- Company's Unique Algorithm Enables Expression Yields up to 50 Times Greater than Competing Approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal Health ... animal health companies to hear from animal health companies with the newest technology. ... licensing agreements or distribution contracts. This meeting is one of the only ...
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... six-month periods ended June 30, 2015. Biorem,s complete second quarter financial ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , ... 2014 , 2015 , 2014 Revenue , ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Fibrillation, EP Mapping and ... PCI and Additional Complex Procedures, ST. LOUIS, ... announced today that more than 10,000 procedures have ... utilizes,advanced, magnet-guided navigational technology intended to help,electrophysiologists and ...
... is showcasing its,motion management systems at this year,s ... 8-13, 2007, at the Palau de,Congresos de Catalunya ... motion management and patient positioning at the,Elekta booth ... "Holding still for 10 minutes? Bet you ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today provided ... Novartis focused on the development and commercialization of,BCR-ABL ... and drug resistant,Chronic Myelogenous Leukemia (CML). Under ... number of,potential drug candidates, with the anticipated timeline ...
Cached Biology Technology:Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 2Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 3Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO 2SGX Provides Update on BCR-ABL Collaboration 2SGX Provides Update on BCR-ABL Collaboration 3
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... The December 2009 issue of the Journal ... Christopher Ahern (The University of British Columbia, Vancouver) and ... other K+ channels using in vivo nonsense suppression technology. ... www.jgp.org ). According to Riccardo Olcese (UCLA) in ...
... of New Hampshire assistant professors have received prestigious ... (CAREER) grants. Vaughn Cooper of the department of ... to better understand beneficial mutations in bacteria by ... White of the mechanical engineering department received $400,000 ...
... general rule among mammals that larger males sire more ... Coltman has found a genetic quirk that might make ... Big, heavy males mountain goats shove lightweight Romeos ... males pass their physical attributes and mating success to ...
Cached Biology News:2 UNH faculty receive $1.4M in CAREER grants from NSF 2
MOUSE ANTI RAT RT1Bu Immunogen: Rat thymocyte membrane glycoproteins...
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
... Diagnostics Cytomegalovirus (CMV) pp65 Antigenemia Immunofluorescence Assay ... of lower matrix protein pp65 of CMV ... Components: Erythrocyte Lysis ... containing 220 mL of buffered ammonium chloride. ...
Biology Products: